These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 18992790)
21. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine. Ambrus CM; Stadler I; Toumbis CA; Stadler A; Anthone S; Anthone R; DeAlarcon P; Deshpande G; Conway J; Vladutiu AO; Ambrus JL J Med; 1999; 30(3-4):211-24. PubMed ID: 17312675 [TBL] [Abstract][Full Text] [Related]
22. Transfusion-associated iron overload. Hollán SR Curr Opin Hematol; 1997 Nov; 4(6):436-41. PubMed ID: 9359002 [TBL] [Abstract][Full Text] [Related]
23. Increased non-transferrin bound iron in plasma-depleted SAG-M red blood cell units. Marwah SS; Blann A; Harrison P; Lumley MA; Wright J; McDowell J; Phillips JD; Rea C; Bareford D Vox Sang; 2002 Apr; 82(3):122-6. PubMed ID: 11952985 [TBL] [Abstract][Full Text] [Related]
24. [Posttransfusion iron overload]. Korsak J Pol Merkur Lekarski; 2011 Mar; 30(177):177-80. PubMed ID: 21544993 [TBL] [Abstract][Full Text] [Related]
25. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Cazzola M; Della Porta MG; Malcovati L Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076 [TBL] [Abstract][Full Text] [Related]
26. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. Marsella M; Borgna-Pignatti C Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709 [TBL] [Abstract][Full Text] [Related]
27. [Iron dysregulation and anemias]. Ikuta K Rinsho Ketsueki; 2015 Oct; 56(10):1903-13. PubMed ID: 26458428 [TBL] [Abstract][Full Text] [Related]
28. [Pathogenesis of transfusional iron overload and iron chelation therapy]. Ozawa K Rinsho Ketsueki; 2009 Jul; 50(7):527-31. PubMed ID: 19638719 [No Abstract] [Full Text] [Related]
29. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Brissot P; Ropert M; Le Lan C; Loréal O Biochim Biophys Acta; 2012 Mar; 1820(3):403-10. PubMed ID: 21855608 [TBL] [Abstract][Full Text] [Related]
30. Blood transfusion increases radical promoting non-transferrin bound iron in preterm infants. Hirano K; Morinobu T; Kim H; Hiroi M; Ban R; Ogawa S; Ogihara H; Tamai H; Ogihara T Arch Dis Child Fetal Neonatal Ed; 2001 May; 84(3):F188-93. PubMed ID: 11320046 [TBL] [Abstract][Full Text] [Related]
31. Iron chelation for iron overload secondary to transfusions of packed red blood cells. Cid J Clin Adv Hematol Oncol; 2014 Mar; 12(3):184-5. PubMed ID: 24927267 [No Abstract] [Full Text] [Related]
32. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Kontoghiorghes GJ Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643 [TBL] [Abstract][Full Text] [Related]
33. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine. Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124 [TBL] [Abstract][Full Text] [Related]
34. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Wu KH; Chang JS; Tsai CH; Peng CT Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011 [TBL] [Abstract][Full Text] [Related]
35. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major. Waheed N; Ali S; Butt MA J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931 [TBL] [Abstract][Full Text] [Related]
36. Lack of non-transferrin-bound iron in heart transplant recipients. Przybylowski P; Malyszko J; Levin-Iaina N; Malyszko JS Transplant Proc; 2011 Oct; 43(8):3068-70. PubMed ID: 21996227 [TBL] [Abstract][Full Text] [Related]
37. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes. Imran F; Phatak P Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988 [TBL] [Abstract][Full Text] [Related]
38. Effect of blood transfusion on serum iron and transferrin saturation. Saxena S; Shulman IA; Johnson C Arch Pathol Lab Med; 1993 Jun; 117(6):622-4. PubMed ID: 8503735 [TBL] [Abstract][Full Text] [Related]
39. Transfusion therapy for sickle cell disease: a balancing act. Chou ST Hematology Am Soc Hematol Educ Program; 2013; 2013():439-46. PubMed ID: 24319217 [TBL] [Abstract][Full Text] [Related]